Timing-dependent skin toxicity phenotypes during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma. - Hashimoto M; Inoki L; Yamamoto Y; Fukuokaya W; Yanagisawa T; Mori K; Maenosono R; Yoshikawa Y; Tsujino T; Saruta M; Nukaya T; Oishi Y; et al. (International journal of clinical oncology, 2026)